Cambridge Healthtech Institute’s 5th Annual

Gene Therapy Manufacturing

Scaling up and Supplying Vector-Based Gene Therapies

August 27-28, 2020


Cambridge Healthtech Institute’s Gene Therapy Manufacturing meeting tackles the practical challenges facing the process development, scale-up and production of viral vector-based gene therapies, tackling key topics such as AAV, lentivirus, and retrovirus upstream and downstream process development, scale-up, viral clearance, and viral vector supply for clinical and commercial manufacturing.


Cover will include, but is not limited to:

  • Production strategies for commercializing gene therapies
  • Strategies to optimize AAV production
  • Strategies to optimize lentiviral production
  • New technologies - adherent and suspension-based platforms
  • Bioreactors
  • Raw and ancillary materials
  • Critical quality attributes
  • Facility design
  • Manufacturing strategies and predicting patient populations
  • Formulation, stability, and delivery


If you would like to submit a proposal to give a presentation at this meeting, please click here.


The deadline for priority consideration is February 21, 2020.


All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


For more details on the conference, please contact:
Daniel Barry
Senior Conference Director
Cambridge Healthtech Institute

Phone: (+1) 781-247-6266


For partnering and sponsorship information, please contact:

Companies A-K
Sherry Johnson
Senior Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1359

Companies L-Z
Carolyn Cooke
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412

Premier Sponsors: